Janux Therapeutics (JANX) Non-Current Deffered Revenue (2020 - 2026)

Janux Therapeutics (JANX) has reported Non-Current Deffered Revenue for 5 consecutive years, with $8.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Non-Current Deffered Revenue changed N/A year-over-year to $8.7 million; the TTM figure through Mar 2026 stood at $8.7 million (changed N/A YoY), while the FY2022 annual figure was $2.2 million, up 217.29% from the prior year.
• Non-Current Deffered Revenue advanced to $8.7 million in Q1 2026 per JANX's latest filing, from $307000.0 in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $8.7 million in Q1 2026 and bottomed at $307000.0 in Q2 2023.
• Historically, Non-Current Deffered Revenue has averaged $3.6 million across 3 years, with a median of $3.0 million in 2022.
• Annual changes were most pronounced in 2022 — Non-Current Deffered Revenue surged 217.29% — and 2023, when it plunged 94.2%.
• Janux Therapeutics' Non-Current Deffered Revenue stood at $2.2 million in 2022, then slumped by 86.18% to $307000.0 in 2023, then jumped by 2726.06% to $8.7 million in 2026.
• Business Quant data shows JANX's Non-Current Deffered Revenue at $8.7 million in Q1 2026, $307000.0 in Q2 2023, and $1.4 million in Q1 2023.